Procarta Biosystems

Developer of oligonucleotide-based therapeutics against antimicrobial resistance

placeNorwich, England, United Kingdom calendar_todayFounded 2007 groups3 employees language procartabio.com

Registered entities

Innovation

10 patent families (4 granted) — focus: Chemistry & metallurgy, Human necessities; filing pace dormant. Cited 860 times.

YearFilings
20123
20133
20145
20152
20163
20173
20186
20192

Investor mix

16 investors on record; lead investors include REPAIR Impact Fund, UK Innovation Science & Seed Fund, Morningside.

Investor typeCountShare
Venture capital638%
Private equity213%
Other / undisclosed850%
Coming soon